BACKGROUND: Pasireotide (SOM230), a long-acting somatostatin analogue (LAR), has improved agonist activity at somatostatin receptors. We tested the effect of SOM230 on insulin secretion, serum glucose concentrations, tumor growth, and survival using an MEN1 transgenic mouse model. METHODS: Eight 12-month-old conditional Men1 knockout mice with insulinoma were assessed. The treatment (n = 4) and control groups (n = 4) received monthly subcutaneous injections of SOM230 or PBS. Serum insulin and glucose levels were determined by enzyme-linked immunosorbent assay and enzymatic colorimetric assay, respectively. Tumor activity, growth, and apoptosis were determined by microPET/CT scan and histologic analysis. RESULTS: On day 7, there was a decrease in serum insulin levels from 1.06 ± 0.28 μg/L to 0.37 ± 0.17 μg/L (P = .0128) and a significant increase in serum glucose from 4.2 ± 0.45 mmol/L to 7.12 ± 1.06 mmol/L (P = .0075) in the treatment group but no change in the control group. Tumor size was less in the treatment group (2,098 ± 388 μm(2)) compared with the control group (7,067 ± 955 μm(2); P = .0024). Furthermore, apoptosis was increased in the treatment group (6.9 ± 1.23%) compared with the control group (0.29 ± 0.103%; P = .002). CONCLUSION: SOM230 demonstrates antisecretory, antiproliferative, and proapoptotic activity in our MEN1 model of insulinoma. Further studies of the effects of SOM230 in PNET patients with MEN1 mutations are warranted.
BACKGROUND: Pasireotide (SOM230), a long-acting somatostatin analogue (LAR), has improved agonist activity at somatostatin receptors. We tested the effect of SOM230 on insulin secretion, serum glucose concentrations, tumor growth, and survival using an MEN1 transgenic mouse model. METHODS: Eight 12-month-old conditional Men1 knockout mice with insulinoma were assessed. The treatment (n = 4) and control groups (n = 4) received monthly subcutaneous injections of SOM230 or PBS. Serum insulin and glucose levels were determined by enzyme-linked immunosorbent assay and enzymatic colorimetric assay, respectively. Tumor activity, growth, and apoptosis were determined by microPET/CT scan and histologic analysis. RESULTS: On day 7, there was a decrease in serum insulin levels from 1.06 ± 0.28 μg/L to 0.37 ± 0.17 μg/L (P = .0128) and a significant increase in serum glucose from 4.2 ± 0.45 mmol/L to 7.12 ± 1.06 mmol/L (P = .0075) in the treatment group but no change in the control group. Tumor size was less in the treatment group (2,098 ± 388 μm(2)) compared with the control group (7,067 ± 955 μm(2); P = .0024). Furthermore, apoptosis was increased in the treatment group (6.9 ± 1.23%) compared with the control group (0.29 ± 0.103%; P = .002). CONCLUSION: SOM230 demonstrates antisecretory, antiproliferative, and proapoptotic activity in our MEN1 model of insulinoma. Further studies of the effects of SOM230 in PNET patients with MEN1 mutations are warranted.
Authors: S Petersenn; J Schopohl; A Barkan; P Mohideen; A Colao; R Abs; A Buchelt; Y-Y Ho; K Hu; A J Farrall; S Melmed; B M K Biller Journal: J Clin Endocrinol Metab Date: 2010-04-21 Impact factor: 5.958
Authors: H-C Jennifer Shen; Mei He; Anathea Powell; Asha Adem; Dominique Lorang; Charles Heller; Amelia C Grover; Kris Ylaya; Stephen M Hewitt; Stephen J Marx; Allen M Spiegel; Steven K Libutti Journal: Cancer Res Date: 2009-02-10 Impact factor: 12.701
Authors: Joost van der Hoek; Wouter W de Herder; Richard A Feelders; Aart-Jan van der Lely; Piet Uitterlinden; Viktor Boerlin; Christian Bruns; Kwai W Poon; Ian Lewis; Gisbert Weckbecker; Tillmann Krahnke; Leo J Hofland; Steven W Lamberts Journal: J Clin Endocrinol Metab Date: 2004-02 Impact factor: 5.958
Authors: J Bertherat; F Tenenbaum; K Perlemoine; C Videau; J L Alberini; B Richard; B Dousset; X Bertagna; J Epelbaum Journal: J Clin Endocrinol Metab Date: 2003-11 Impact factor: 5.958
Authors: Chandra K Maharjan; Po Hien Ear; Catherine G Tran; James R Howe; Chandrikha Chandrasekharan; Dawn E Quelle Journal: Cancers (Basel) Date: 2021-10-12 Impact factor: 6.639
Authors: Naris Nilubol; ZiQiang Yuan; Giulio F Paciotti; Lawrence Tamarkin; Carmen Sanchez; Kelli Gaskins; Esther M Freedman; Shugeng Cao; Jielu Zhao; David G I Kingston; Steven K Libutti; Electron Kebebew Journal: J Natl Cancer Inst Date: 2018-09-01 Impact factor: 13.506
Authors: Tracey L Smith; Ziqiang Yuan; Marina Cardó-Vila; Carmen Sanchez Claros; Asha Adem; Min-Hui Cui; Craig A Branch; Juri G Gelovani; Steven K Libutti; Richard L Sidman; Renata Pasqualini; Wadih Arap Journal: Proc Natl Acad Sci U S A Date: 2016-02-16 Impact factor: 11.205
Authors: Maria Luisa Brandi; Sunita K Agarwal; Nancy D Perrier; Kate E Lines; Gerlof D Valk; Rajesh V Thakker Journal: Endocr Rev Date: 2021-03-15 Impact factor: 19.871